Browse the corpus
Walk the Even Hospital Database by book and chapter — the raw source passages that ground Ask, DDx, and the rest.
3 passages
Ethacrynic acid is a medication used in the management and treatment of chronic heart failure. It is in the loop diuretic class of drugs. This activity describes the indications, action, and contraindications for ethacrynic acid as a valuable agent in managing fluid overload and CHF. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the healthcare team in the management of patients with CHF and related conditions. Objectives: Explain the treatment considerations for patients with chronic heart failure and a sulfa allergy. Describe the adverse effects and contraindications of ethacrynic acid. Review the appropriate monitoring for patients on ethacrynic acid therapy. Outline some interprofessional team strategies for improving care coordination and communication to advance ethacrynic acid and improve outcomes. Access free multiple choice questions on this topic.
Currently, there is no antidote described in the literature for the toxicity of ethacrynic acid. Toxicity usually occurs in elderly patients with diminished renal function leading to volume depletion and, in some cases, toxicity. When adverse side effects occur, rapid discontinuation of ethacrynic acid and supportive care can lead to the resolution of symptoms.[3]
Ethacrynic acid is usually reserved for patients with sulfa allergies. The interprofessional healthcare team should be aware of the drug's rapid onset and monitor the dosages of the drug to avoid hypovolemia and electrolyte imbalances. Pharmacists and clinicians are to pay close attention to patients with renal failure and adjust therapeutic levels of ethacrynic acid accordingly. Nurses should be aware of the signs of adverse events so they can report these promptly to the ordering clinician. To improve outcomes, monitor blood pressure, and avoid concurrent use of other ototoxic medications. If ototoxicity, hepatotoxicity, or electrolyte imbalances are suspected, ethacrynic acid therapy should stop immediately, and the patient should receive appropriate supportive care and symptom management. Utilizing interprofessional team strategies will result in better therapeutic outcomes and fewer adverse events with ethacrynic acid, driving better patient outcomes. [Level 5]